NSCLC Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

DelveInsight's, "Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight 2025" report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Non-Small-Cell Lung cancer (NSCLC) pipeline landscape. It covers the NSCLC pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NSCLC Therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the NSCLC Pipeline. Dive into DelveInsight's comprehensive report today! @ NSCLC Pipeline Outlook [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the NSCLC Pipeline Report

* In May 2025, Suzhou Junjing BioSciences Co., Ltd . announced a Phase II clinical study evaluating JS111 capsules (AP-L1898) as monotherapy in patients with advanced NSCLC harboring EGFR mutations.Approximately 3 to 42 treatment-naive patients with EGFR mutation-positive locally advanced, metastatic, or recurrent NSCLC will be enrolled.Based on prior safety, PK, and efficacy data, two dose levels-160 mg QD and 240 mg QD-will be tested to assess safety, tolerability, PK, and preliminary efficacy, and to determine the recommended Phase II dose (RP2D), as referenced in Section 4.3.
* In May 2025, AstraZeneca conducted a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody rilvegostomig (AZD2936) is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.
* In May 2025, Revolution Medicines Inc . organized a Phase 3 study designed to evaluate whether treatment with daraxonrasib will improve progression free survival (PFS) or overall survival (OS) compared to docetaxel chemotherapy in patients with NSCLC who were previously treated. Patients will be randomized in a 1:1 ratio to receive daraxonrasib or docetaxel chemotherapy.
* In May 2025, Amgen announced a study is to characterize safety and efficacy of 2 dose levels of AMG 193 by investigator, and to evaluate AMG 193 monotherapy efficacy by Blinded Independent Central Review (BICR).
* DelveInsight's NSCLC Pipeline report depicts a robust space with 4+ active players working to develop 4+ pipeline therapies for NSCLC treatment.
* The leading NSCLC Companies such as GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc . and others.
* Promising NSCLC Pipeline Therapies such as Brigatinib, Tyrosine kinase inhibitor, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab , and others.

Stay ahead with the most recent pipeline outlook for NSCLC. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ NSCLC Treatment Drugs [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

NSCLC Emerging Drugs Profile

* AMG 510: Amgen

AMG 510 is being developed by Amgen. Phase 1 clinical trials were completed in late 2020. Because the G12C KRAS mutation is relatively common in some cancer types, 14% of non-small-cell lung cancer adenocancer patients and 5% of colorectal cancer patients, and AMG 510 is the first drug candidate to target this mutation, there have been high expectations for the drug. The Food and Drug Administration has granted a fast track designation to AMG 510 for the treatment of metastatic non-small-cell lung cancer with the G12C KRAS mutation. The drug is in preregistration stage for the treatment of NSCLC.

* CMP 001: Cytos Biotechnology

CMP 001 is a short piece of DNA, called an oligonucleotide that Checkmate designed to mimic the DNA of bacteria. It encapsulated the DNA in noninfectious virus-like particles, or VLPs. The company created CMP-001 to be administered directly to a tumor. When this occurs, the immune system sees VLPs as foreign. It generates immune cells called antigen presenting cells that release the DNA from the VLPs. CMP 001 is in phase 1 of clinical trials for the treatment of non-small cell lung cancer.

NSCLC.

The NSCLC Pipeline Report Provides Insights into

* The report provides detailed insights about companies that are developing therapies for the treatment of NSCLC with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for NSCLC Treatment.
* NSCLC Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* NSCLC Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the NSCLC market

Explore groundbreaking therapies and clinical trials in the NSCLC Marketed and Pipeline Drugs. Access DelveInsight's detailed report now! @ New NSCLC Drugs [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

NSCLC Companies

GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc . and others.

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

* Subcutaneous
* Intravenous
* Oral
* Parenteral
* Intramuscular
* Molecule Type

NSCLC Products have been categorized under various Molecule types such as

* Small molecules
* Peptides
* Polymer
* Gene Therapy
* Monoclonal antibodies
* Product Type

Unveil the future of NSCLC Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ NSCLC Market Drivers and Barriers [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Scope of the NSCLC Pipeline Report

* Coverage- Global
* NSCLC Companies- GlaxoSmithKline, Novartis, AstraZeneca, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck, Millennium Pharmaceuticals, Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol Myers Squibb, Sanofi, IO Biotech, Transgene, Immutep S.A., Daiichi Sankyo, Inc., Regeneron Pharmaceuticals, Hanmi Pharmaceutical Company Limited, and TYK Medicines Inc . and others.
* NSCLC Pipeline Therapies- Brigatinib, Tyrosine kinase inhibitor, Osimertinib, Gefitinib, SSGJ-707, Vandetanib, Atezolizumab, Tiragolumab , and others.
* NSCLC Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* NSCLC Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on NSCLC Therapies and clinical trials. Download DelveInsight's in-depth pipeline report today! @ NSCLC Companies, Key Products and Unmet Needs [https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-nsclc-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Contents

* Introduction
* Executive Summary
* Non-Small-Cell Lung cancer (NSCLC): Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Non-Small-Cell Lung cancer (NSCLC) - DelveInsight's Analytical Perspective
* In-depth Commercial Assessment
* Late Stage Products (Pre Registration)
* AMG 510: Amgen
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Drug Name: Company Name
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* CMP 001: Cytos Biotechnology
* Drug profiles in the detailed report.....
* Inactive Products
* Non-Small-Cell Lung cancer (NSCLC) Key Companies
* Non-Small-Cell Lung cancer (NSCLC) Key Products
* Non-Small-Cell Lung cancer (NSCLC)- Unmet Needs
* Non-Small-Cell Lung cancer (NSCLC)- Market Drivers and Barriers
* Non-Small-Cell Lung cancer (NSCLC)- Future Perspectives and Conclusion
* Non-Small-Cell Lung cancer (NSCLC) Analyst Views
* Non-Small-Cell Lung cancer (NSCLC) Key Companies
* Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=nsclc-pipeline-appears-robust-with-10-key-pharma-companies-actively-working-in-the-therapeutics-segment-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-nsclc-pipeline-insight

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.